Array BioPharma Inc. (ARRY) belonging to the Medical sector has declined -1.56% and closed its last trading session at $10.74.
The company reported its EPS on 02/09/2017. Currently, the stock has a 1 Year Price Target of $12.5.
The consensus recommendation, according to Zacks Investment research, is 1.44. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.44 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Array BioPharma Inc. on 02/09/2017 reported its EPS as $-0.14 with the analysts projecting the EPS of the stock as $-0.18. The company beat the analyst EPS Estimate with the difference of $0.04. This shows a surprise factor of 22.2%.
Many analysts have provided their estimated foresights on Array BioPharma Inc. Earnings, with 9 analysts believing the company would generate an Average Estimate of $-0.17.
Whereas they predicted High and Low Earnings Estimate as $0.08 and $-0.31 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.16.
Analysts are also projecting an Average Revenue Estimate for Array BioPharma Inc. as $38.94 Million in the Current Quarter. This estimate is provided by 9 analysts.
The High Revenue estimate is predicted as 97 Million, while the Low Revenue Estimate prediction stands at 27 Million. The company’s last year sales total was 43.05 Million.
For the Current Quarter, the growth estimate for Array BioPharma Inc. is -6.3%, while for the Next Quarter the stock growth estimate is -29.4%.
The Company got Downgrade by JP Morgan on 3-Feb-17 from Overweight to Neutral.
Insider Trades for Array BioPharma Inc. show that the latest trade was made on 28 Oct 2016 where Orwin (John A), the Director completed a transaction type “Buy” in which 5000 shares were traded at a price of $0.
Over the period of 6 months, Insider Purchases show a total of 6 transaction in which 3203980 shares were traded. 1 Insider Sales transactions were made totaling 25000 shares traded.
8 analysts projected Price Targets for Array BioPharma Inc.. The analysts believe that the company stock price could grow as high as $15. The Low Price target projection by analysts is $8 and the Mean Price Target is $12.5.
Array BioPharma Inc. (ARRY) has the market capitalization of $1.89 Billion. The company rocked its 52-Week High of $13.4 on Feb 10, 2017 and touched its 52-Week Low of $2.6 on Apr 1, 2016.
The stock has Return on Assets (ROA) of -49.5 percent. Return on Equity (ROE) stands at 754.4% and Return on Investment (ROI) of -108.5 percent.
The stock is currently showing YTD performance of 22.18 Percent. The company has Beta Value of 2.11 and ATR value of 0.58. The Weekly and Monthly Volatility stands at 5.09% and 4.88%.